Skip to content

Trial · Interventional

RecruitingNot applicableRegistry data

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

NCTNCT07144527 (opens ClinicalTrials.gov in a new tab)Other id2305604-1
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Recruiting
Phase
Not applicable
Enrollment
40 participants (estimated)
Sponsor
Scott Silveira · Other
Design
Randomized · Quadruple masking
Countries
1 country

United States

Start
21 Feb 2026
Primary completion
30 Dec 2026 (estimated)
Completion
1 Jan 2027 (estimated)
First posted
27 Aug 2025
Last update posted
7 Oct 2026
Conditions
Aging · Frailty · Exercise Tolerance · Healthy Male and Female Subjects

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
202620272028
  1. N/A

    Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

    NCT07144527

    21 Feb 2026 to est. 1 Jan 2027

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of nicotinamide mononucleotide (NMN) combined with trimethylglycine (TMG) supplementation, compared to NMN alone. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults. The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels. The supplements have been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.

Interventions

  • NMN and TMG (Euexia)Dietary supplement
  • Nicotinamide Mononucleotide (NMN)Dietary supplement
  • PlaceboDietary supplement

Arms4

  • Experimental

    Arm 1 - NMN with TMG -> Placebo

    Participants receive NMN with TMG during Period 1, followed by Placebo during Period 2 after a washout. Assigned Interventions: NMN with TMG; Placebo.

  • Experimental

    Arm 2 - Placebo -> NMN with TMG

    Participants receive Placebo during Period 1, followed by NMN with TMG during Period 2 after a washout. Assigned Interventions: Placebo; NMN with TMG.

  • Experimental

    Arm 3 - NMN -> Placebo

    Participants receive Nicotinamide Mononucleotide (NMN) during Period 1, followed by Placebo during Period 2 after a washout. Assigned Interventions: NMN; Placebo.

  • Experimental

    Arm 4 - Placebo -> NMN

    Participants receive Placebo during Period 1, followed by NMN during Period 2 after a washout. Assigned Interventions: Placebo; NMN.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Time to Fatigue During Constant Work Rate Cycle Ergometry (tLIM).

    Time frame · Measured at the beginning and end of each 4-week intervention period.

    Registry description

    Duration (in seconds) that participants can sustain a constant submaximal workload on a cycle ergometer until volitional fatigue. This is a validated surrogate for submaximal exercise tolerance.

Secondary outcomes(5)

  1. Peak Oxygen Uptake (VO2max)

    Time frame · Measured at the beginning and end of each 4-week intervention period.

    Registry description

    Maximum oxygen consumption (ml/kg/min) achieved during graded exercise testing.

  2. Lactate Threshold

    Time frame · Measured at the beginning and end of each 4-week intervention period.

    Registry description

    Workload or oxygen consumption corresponding to the point at which blood lactate concentration rises above baseline, assessed via graded exercise testing and gas exchange sampling.

  3. Anaerobic Work Capacity

    Time frame · Measured at the beginning and end of each 4-week intervention period.

    Registry description

    Cumulative work performed above the critical power, calculated from cycle ergometer testing.

  4. Critical Power

    Time frame · Measured at the beginning and end of each 4-week intervention period.

    Registry description

    The asymptote of the power-duration relationship. A work rate reflecting sustainable aerobic work capacity.

  5. Circulating NAD+ and Related Metabolites

    Time frame · Measured at the beginning and end of each 4-week intervention period.

    Registry description

    Plasma concentrations of NAD+, NMN, and related metabolites measured by targeted metabolomics.

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 60 Years up to 80 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Adults aged 60 to 80 years, of any sex * Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study * Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no significant valvular heart disease, no ischemic changes, and no other clinically significant abnormalities, plus confirmation that no new cardiovascular symptoms (e.g., chest pain, dyspnea, syncope) or changes in health status have occurred since testing * Montreal Cognitive Assessment (MoCA) score of 26 or higher * Free from acute or uncontrolled chronic medical conditions that would pose a risk or interfere with study participation * Physically capable of engaging in structured exercise involving moderate to vigorous intensity stationary cycling * Successful completion of a graded exercise test (e.g., stationary bike) without significant adverse events or contraindications * Ability to attend at least four in-person laboratory visits in Beverly Hills, California * Non-smoker for at least 12 months * Able to provide informed consent and comply with study procedures * Willing to refrain from initiating new exercise, dietary supplement, or medication regimens during the study Exclusion Criteria: * Severe cardiovascular disease (e.g., recent myocardial infarction \<6 months, unstable angina, uncontrolled hypertension \>160/100 mmHg) * Severe respiratory conditions (e.g., advanced COPD or other conditions preventing exercise participation) * Significant neurological impairments that hinder comprehension of instructions or participation in exercise * Terminal illness or conditions limiting life expectancy or ability to complete the study * Severe cognitive impairment preventing informed consent, protocol adherence, or comprehension of interventions * Significant orthopedic limitations or injuries that prevent safe exercise participation * Use of NMN, NR, or other NAD+-altering supplements within the past 14 weeks * Anticipated or current alcohol consumption \>2 drinks per week, or unwillingness to abstain from alcohol during the study * Current substance abuse affecting study participation or adherence * Other acute or chronic health conditions judged by the investigators to pose risk or interfere with study objectives * Non-compliance with study requirements, withdrawal of informed consent, or unforeseen circumstances compromising completion * Any condition which, in the opinion of the investigator, would interfere with study participation or interpretation of results

PepBank is a research reference. Talk to a doctor before you use any peptide.